share_log

Altimmune | 10-Q: Q3 2024 Earnings Report

Altimmune | 10-Q: Q3 2024 Earnings Report

Altimmune | 10-Q:2024財年三季報
美股SEC公告 ·  2024/11/12 21:13

牛牛AI助理已提取核心訊息

Altimmune reported a net loss of $22.8 million for Q3 2024, compared to $20.7 million in Q3 2023, with total revenue declining to $5,000 from $362,000. Research and development expenses increased 8% to $19.8 million, primarily driven by the advancement of pemvidutide clinical trials. The company ended the quarter with $139.4 million in cash and investments.The company achieved significant progress with pemvidutide, completing enrollment in the Phase 2b IMPACT trial for MASH treatment, with top-line data expected in Q2 2025. Additionally, Altimmune successfully concluded its End-of-Phase 2 Meeting with the FDA, reaching agreement on the design of Phase 3 registrational program for obesity treatment, which will include four trials enrolling approximately 5,000 subjects.Management maintains that current cash reserves are sufficient to fund operations for at least 12 months. The company continues to focus on developing treatments for obesity and liver diseases, with pemvidutide showing promising results in body composition analysis, including 78.1% of weight loss derived from adipose tissue and only 21.9% from lean mass in the MOMENTUM Phase 2 obesity trial.
Altimmune reported a net loss of $22.8 million for Q3 2024, compared to $20.7 million in Q3 2023, with total revenue declining to $5,000 from $362,000. Research and development expenses increased 8% to $19.8 million, primarily driven by the advancement of pemvidutide clinical trials. The company ended the quarter with $139.4 million in cash and investments.The company achieved significant progress with pemvidutide, completing enrollment in the Phase 2b IMPACT trial for MASH treatment, with top-line data expected in Q2 2025. Additionally, Altimmune successfully concluded its End-of-Phase 2 Meeting with the FDA, reaching agreement on the design of Phase 3 registrational program for obesity treatment, which will include four trials enrolling approximately 5,000 subjects.Management maintains that current cash reserves are sufficient to fund operations for at least 12 months. The company continues to focus on developing treatments for obesity and liver diseases, with pemvidutide showing promising results in body composition analysis, including 78.1% of weight loss derived from adipose tissue and only 21.9% from lean mass in the MOMENTUM Phase 2 obesity trial.
Altimmune在2024年第三季度報告的淨虧損爲2280萬美元,而2023年第三季度爲2070萬美元,總營業收入從362,000下降至5,000美元。研發支出增加8%,達到1980萬美元,主要是由於pemvidutide臨牀試驗的推進。公司在本季度末擁有現金和投資13940萬美元。該公司在pemvidutide方面取得了重要進展,完成了MASH治療的20億IMPACt試驗的入組,預計將在2025年第二季度獲得最終數據。此外,Altimmune成功結束了與FDA的二期結束會議,就肥胖治療的三期註冊項目設計達成一致,該項目將包括四個試驗,招募約5,000名受試者。管理層認爲目前的現金儲備足以支持至少12個月的運營。公司繼續專注於開發肥胖和肝病的治療,pemvidutide在身體成分分析中顯示出有希望的結果,包括在MOMENTUm二期肥胖試驗中,78.1%的體重減輕來自脂肪組織,僅21.9%來自瘦體重。
Altimmune在2024年第三季度報告的淨虧損爲2280萬美元,而2023年第三季度爲2070萬美元,總營業收入從362,000下降至5,000美元。研發支出增加8%,達到1980萬美元,主要是由於pemvidutide臨牀試驗的推進。公司在本季度末擁有現金和投資13940萬美元。該公司在pemvidutide方面取得了重要進展,完成了MASH治療的20億IMPACt試驗的入組,預計將在2025年第二季度獲得最終數據。此外,Altimmune成功結束了與FDA的二期結束會議,就肥胖治療的三期註冊項目設計達成一致,該項目將包括四個試驗,招募約5,000名受試者。管理層認爲目前的現金儲備足以支持至少12個月的運營。公司繼續專注於開發肥胖和肝病的治療,pemvidutide在身體成分分析中顯示出有希望的結果,包括在MOMENTUm二期肥胖試驗中,78.1%的體重減輕來自脂肪組織,僅21.9%來自瘦體重。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 310

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。